# COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction

Study · id `cardio:ct-nct02744677` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02744677](<https://clinicaltrials.gov/study/NCT02744677>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02744677

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 108 participants.

## Technical summary

Registry record NCT02744677. Non-randomized; no masking; primary purpose treatment. Start 2016-07-05 (actual); primary completion 2026-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 108 participants (planned count; ClinicalTrials.gov record NCT02744677, source copy `cardio:ctgov-nct02744677-2026-07-23`, retrieved 2026-10-26)
- Started: 2016-07-05 (actual) (ClinicalTrials.gov record NCT02744677, source copy `cardio:ctgov-nct02744677-2026-07-23`, retrieved 2026-10-26)
- Primary completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT02744677, source copy `cardio:ctgov-nct02744677-2026-07-23`, retrieved 2026-10-26)
- Completion: 2031-06 (anticipated) (ClinicalTrials.gov record NCT02744677, source copy `cardio:ctgov-nct02744677-2026-07-23`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02744677, source copy `cardio:ctgov-nct02744677-2026-07-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02744677-2026-07-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- Condition: Complex Congenital Heart Defect
- Condition: Dysfunctional RVOT Conduit
- Condition: Pulmonary Valve Insufficiency
- Condition: Pulmonary Valve Degeneration
- Intervention (Device): SAPIEN 3/SAPIEN 3 Ultra RESILIA THV
- Intervention (Device): SAPIEN 3 THV
- Intervention (Device): SAPIEN 3 Ultra RESILIA THV
- Lead sponsor: Edwards Lifesciences
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry condition terms include this condition: Congenital heart disease (`core:congenital-heart-disease`)
- Registry intervention name matches this record: SAPIEN 3 transcatheter heart valve (`cardio:sapien-3`)
- Registry lists this organization as the lead sponsor: Edwards Lifesciences (`cardio:edwards-lifesciences`)

## Provenance

Content hash: 64ed655104e3d66235ba6f9c89c070d58a6834ca1e764229c22ca00d5faf7f4b
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
